Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 231.27% | 197.86% | 175.97% | 105.89% | 25.25% |
| Total Depreciation and Amortization | -- | -53.04% | -13.88% | -13.88% | -13.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,217.60% | -634.01% | -474.55% | -317.81% | -52.50% |
| Change in Net Operating Assets | 82.09% | -505.09% | -177.96% | -177.96% | -177.96% |
| Cash from Operations | 94.75% | 68.77% | 44.17% | 23.63% | 1.77% |
| Capital Expenditure | -- | 100.00% | 100.00% | 80.42% | 60.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 100.00% | 80.42% | 60.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -21,961.43% | -23,771.43% | -25,900.84% | -14,842.79% | -57.30% |
| Issuance of Common Stock | -- | -- | -- | -84.55% | -67.45% |
| Repurchase of Common Stock | -- | 0.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -173.33% | -117.38% | -111.00% | -99.91% | -88.68% |
| Foreign Exchange rate Adjustments | -103.19% | -89.97% | -77.65% | 10.25% | 1,876.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.63% | -484.34% | -223.19% | -232.38% | -242.52% |